{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angio-oedema-anaphylaxis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ba9835a0-bab7-44e2-a425-1291288d926e --><h2>Changes</h2><!-- end field ba9835a0-bab7-44e2-a425-1291288d926e -->","summary":null,"htmlStringContent":"<!-- begin item b55604d5-3f11-4f50-88ed-25a91cd75288 --><!-- begin field 1da76231-8517-4a46-92f7-ac130f54b752 --><p><strong>March 2020</strong> — minor update. Adverse effect section of non-sedating antihistamines updated to reflect changes to SPC.<strong style=\"font-size: 19.2px;\"> </strong></p><p><strong>November 2018</strong> — minor update. Advice added to prescribing of emergency drug doses relating to checking manufacturers SPC for the specific auto-infector being used. </p><p><strong>January 2018</strong> — minor update. Adverse effect section of non-sedating antihistamines updated to reflect changes to SPC.</p><p><strong>June 2017 </strong>— reviewed. A literature search was conducted in May 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to recommendations have been made.</p><!-- end field 1da76231-8517-4a46-92f7-ac130f54b752 --><!-- end item b55604d5-3f11-4f50-88ed-25a91cd75288 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","lastRevised":"Last revised in November 2018","chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"92114e67-586c-5dca-be33-6536109807d2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 094e77eb-73d5-4c8c-9132-601457d1f527 --><h3>Previous changes</h3><!-- end field 094e77eb-73d5-4c8c-9132-601457d1f527 -->","summary":null,"htmlStringContent":"<!-- begin item 028bce0a-41d9-4c03-95a7-2b29af75cf12 --><!-- begin field f1274b15-55ad-4a54-a216-6ed6fb77ea93 --><p><strong>June 2014 </strong>— minor update. Update to the text regarding the use of adrenal auto-injectors following advice from the Medicines and Healthcare Products Regulatory Agency (MHRA). </p><p><strong>January 2012 </strong>— revised. A literature search was conducted in October 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. This topic now includes recommendations from the National Institute for Health and Care Excellence (NICE) guidance <em>Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode</em>. In addition, the management section has been restructured to improve clarity and navigation. Issued in January 2012.</p><p><strong>February 2011 </strong>— technical update. The Management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the Changes section. Issued in September 2008.</p><p><strong>April 2008 </strong>— minor update to include recommendations from the Working Group of the Resuscitation Council (UK) guideline <em>Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers</em> (January 2008). This includes changes in the dosages of emergency drugs for anaphylaxis. Issued in May 2008.</p><p><strong>January to April 2007 </strong>— this is a new CKS topic, replacing the CKS guidance on Urticaria and angio-oedema. The evidence base has been reviewed in detail, and recommendations are more clearly justified and more transparently linked to the supporting evidence. There are no major changes to the recommendations for the management of angio-oedema. Additional information on the management of anaphylaxis is included.</p><!-- end field f1274b15-55ad-4a54-a216-6ed6fb77ea93 --><!-- end item 028bce0a-41d9-4c03-95a7-2b29af75cf12 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}